Syndax Pharmaceuticals Inc (SNDX) reports promising revenue from Revv Forge launch and outlines strategic growth plans, ...

HC Wainwright restated their buy rating on shares of Syndax Pharmaceuticals (NASDAQ:SNDX – Free Report) in a report published ...

Syndax Pharmaceuticals Inc (NASDAQ:SNDX) is set to release its Q4 2024 earnings on Mar 3, 2025. The consensus estimate for Q4 ...

Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Syndax ...

Q4 2024 Earnings Call Transcript March 3, 2025 Operator: Good day, everyone, and welcome to the Syndax Fourth Quarter and Full Year 2024 Earnings Conference Call. Today’s call is being recorded.

Highlights,Target price adjustments for Syndax Pharmaceuticals reflect varied market sentiment.,Executive decisions on stock ...

Barclays analyst Peter Lawson maintained a Buy rating on Syndax Pharmaceuticals (SNDX – Research Report) today and set a price target of ...

Good day, everyone, and welcome to the Syndax Fourth Quarter and Full Year 2024 Earnings Conference Call. Today's call is being recorded. [Operator Instructions] At this time, I'd like to turn the ...

Scotiabank analyst George Farmer maintained a Hold rating on Syndax Pharmaceuticals (SNDX – Research Report) today and set a price target of ...

Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on March 1, 2025 the Company granted ...

SYNDAX PHARMACEUTICALS ($SNDX) posted quarterly earnings results on Monday, March 3rd. The company reported earnings of -$1.10 per share, missing estimates of -$0.25 ...